Synonyms: CM-082 | CM082 | Example 8 [WO2008033562A2] | EYP-1901 | X-82
Compound class:
Synthetic organic
Comment: Vorolanib (CM082) is a potent and selective, oral clinical stage multi-kinase inhibitor. Targets include all VEGFR isoforms, PDGFR and CSF1R. [1-3]. It is a structural derivative of sunitinib. Vorolanib has anti-angiogenic activity, and is being investigated for anti-tumour effects and utility to treat ocular neovascularisation.
|
|
Bioactivity Comments |
CM082 inhibits proliferation, migration and invasion of HUVECs in vitro, via a VEGFR2-dependent mechanism [1]. The original patent claims for CM082 do not provide quantitiative potency data for target inhibition. |